Associations of serum carotenoids with cardiovascular disease mortality among patients with metabolic dysfunction-associated steatotic liver disease.

IF 3.4 3区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Hepatology Research Pub Date : 2025-08-01 Epub Date: 2025-05-29 DOI:10.1111/hepr.14215

Qian-Qian Wang, Jing Zhu, Lin-Jun Miao, Si-Ang Lv, Guo-Yin Shen, Jun Wu

{"title":"Associations of serum carotenoids with cardiovascular disease mortality among patients with metabolic dysfunction-associated steatotic liver disease.","authors":"Qian-Qian Wang, Jing Zhu, Lin-Jun Miao, Si-Ang Lv, Guo-Yin Shen, Jun Wu","doi":"10.1111/hepr.14215","DOIUrl":null,"url":null,"abstract":"Aim: High cardiovascular disease (CVD) mortality occurred among metabolic dysfunction-associated steatotic liver disease (MASLD) patients with few approved therapies. The aim of this study was to reveal the associations of serum carotenoid concentrations with CVD mortality among MASLD patients.Methods: The two prospective cohort analyses included 1175 MASLD patients from the National Health and Nutrition Examination Survey (NHANES) and 1725 MASLD patients from NHANES III. CVD mortality was ascertained through December 31, 2019. Multivariable Cox proportional hazards regression analysis was carried out to evaluate the associations of serum carotenoid levels with CVD mortality.Results: After multivariable adjustment, per one-unit increment in natural log-transformed serum β-cryptoxanthin was associated with an 85% lower risk of CVD mortality (p = 0.03) among MASLD patients aged <60 years from NHANES and a 92% lower risk of CVD mortality (p = 0.003) among MASLD patients aged <60 years from NHANES III. The adjusted HRs (95% CIs) across tertiles of serum β-cryptoxanthin concentrations were 1.00 (reference), 0.55 (0.12-2.41), 0.02 (0.002-0.24), P trend = 0.03 and 1.00 (reference), 0.47 (0.14-1.58), 0.05 (0.01-0.31), P trend = 0.002, among MASLD patients aged <60 years from NHANES and NHANES III, respectively.Conclusions: In MASLD patients aged <60 years, high serum β-cryptoxanthin concentrations were inversely associated with CVD mortality.","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":"1111-1127"},"PeriodicalIF":3.4000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatology Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/hepr.14215","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/29 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: High cardiovascular disease (CVD) mortality occurred among metabolic dysfunction-associated steatotic liver disease (MASLD) patients with few approved therapies. The aim of this study was to reveal the associations of serum carotenoid concentrations with CVD mortality among MASLD patients.

Methods: The two prospective cohort analyses included 1175 MASLD patients from the National Health and Nutrition Examination Survey (NHANES) and 1725 MASLD patients from NHANES III. CVD mortality was ascertained through December 31, 2019. Multivariable Cox proportional hazards regression analysis was carried out to evaluate the associations of serum carotenoid levels with CVD mortality.

Results: After multivariable adjustment, per one-unit increment in natural log-transformed serum β-cryptoxanthin was associated with an 85% lower risk of CVD mortality (p = 0.03) among MASLD patients aged <60 years from NHANES and a 92% lower risk of CVD mortality (p = 0.003) among MASLD patients aged <60 years from NHANES III. The adjusted HRs (95% CIs) across tertiles of serum β-cryptoxanthin concentrations were 1.00 (reference), 0.55 (0.12-2.41), 0.02 (0.002-0.24), P trend = 0.03 and 1.00 (reference), 0.47 (0.14-1.58), 0.05 (0.01-0.31), P trend = 0.002, among MASLD patients aged <60 years from NHANES and NHANES III, respectively.

Conclusions: In MASLD patients aged <60 years, high serum β-cryptoxanthin concentrations were inversely associated with CVD mortality.

查看原文本刊更多论文

代谢功能障碍相关脂肪变性肝病患者血清类胡萝卜素与心血管疾病死亡率的关系

目的：高心血管疾病（CVD）死亡率发生在代谢功能障碍相关脂肪变性肝病（MASLD）患者中，批准的治疗方法很少。本研究的目的是揭示MASLD患者血清类胡萝卜素浓度与心血管疾病死亡率的关系。方法：两项前瞻性队列分析包括来自国家健康与营养检查调查（NHANES）的1175例MASLD患者和来自NHANES III的1725例MASLD患者。截至2019年12月31日，确定了心血管疾病死亡率。采用多变量Cox比例风险回归分析评估血清类胡萝卜素水平与心血管疾病死亡率的关系。结果：在多变量调整后，在老年MASLD患者中，自然对数转化血清β-隐黄质每增加一个单位，心血管疾病死亡风险降低85% （p = 0.03）

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hepatology Research 医学-胃肠肝病学

CiteScore

8.30

自引率

14.30%

发文量

124

审稿时长

1 months

期刊介绍： Hepatology Research (formerly International Hepatology Communications) is the official journal of the Japan Society of Hepatology, and publishes original articles, reviews and short comunications dealing with hepatology. Reviews or mini-reviews are especially welcomed from those areas within hepatology undergoing rapid changes. Short communications should contain concise definitive information.